Anti-NXP-2 (P140) Ab (RDL)
Also known as: Anti-NXP-2, antinuclear matrix protein 2 antibody, NXP-2 (MJ), NXP2, P140
Use
Anti-NXP-2 antibodies are present in 2-30% of adult DM and 18-25% of JDM. In JDM, they are associated with cutaneous calcinosis cutis. In adult DM, they are significantly associated with the presence of cancer (cancer was found in 13.6% of Anti-NXP-2 positive DM patients).
Special Instructions
Separate serum from cells within one hour of collection and transfer to a plastic transport tube before shipping. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Limitations
This test was developed and its performance characteristics were determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The test results should be interpreted in the context of clinical findings, including medical history, and should not be used as the sole basis for diagnosis.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 82425-0
- 105228-4
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping.
Storage Instructions
Refrigerate or freeze.
Causes for Rejection
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 60 days |